TUMOR SPECIFIC *BCR/ABL1* FISH, QUALITATIVE, OR QUANTITATIVE TESTS

- I. Tumor specific *BCR/ABL1* FISH, qualitative, or quantitative tests (0016U, 0040U, 81206, 81207, 81208, 81479, 88271, 88274, 88275, 88291) in hematologic malignancies is considered **medically necessary** when:
 - A. The member is suspected to have a myeloproliferative neoplasm (i.e., polycythemia vera, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia), **OR**
 - B. The member is undergoing diagnostic workup for:
 - 1. Acute lymphoblastic leukemia (ALL), OR
 - 2. Acute myeloid leukemia (AML), OR
 - 3. Chronic myeloid leukemia (CML), OR
 - 4. B-cell lymphoma, OR
 - C. The member is undergoing monitoring of disease progression or for minimal residual disease (MRD) monitoring using a quantitative test only for:
 - 1. Acute lymphoblastic leukemia (ALL), OR
 - 2. Acute myeloid leukemia (AML), OR
 - 3. Chronic myelogenous leukemia (CML), OR
 - 4. B-cell lymphoma.



©2024 Concert Proprietary Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies 2025.1

DEFINITIONS

- 1. **Myeloproliferative Neoplasms:** Rare overlapping blood diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets. There are seven subcategories of myeloproliferative neoplasms:
 - Chronic myeloid leukemia (CML)
 - Polycythemia vera (PV)
 - Primary myelofibrosis (PMF)
 - Essential thrombocytopenia (ET)
 - Chronic neutrophilic leukemia
 - Chronic eosinophilic leukemia
 - Chronic eosinophilic leukemia-not otherwise specified
 - MPN, unclassifiable (MPN-U)

REFERENCES

- 1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
- 2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1.2024 https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
- 3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Chronic Myeloid Leukemia. Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
- 4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Pediatric Acute Lymphoblastic Leukemia. Version 6.2024. https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf
- 5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Acute Lymphoblastic Leukemia. Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf



©2024 Concert Proprietary Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies 2025.1 Effective: 1/1/2025 Last Revision: 9/9/2024 Last Clinical Review: 8/1/2024

 National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in B-Cell Lymphomas. Version 2.2024. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf



©2024 Concert Proprietary